Loading stock data…
$2.25-0.10 (-4.05%)
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases.
OnKure Therapeutics, Inc. in the Healthcare sector is trading at $2.25 with a market capitalization of $91M. Wall Street consensus targets $15.50 (4 analysts), implying a +588.9% move over the next 12 months. The stock is currently near its 52-week low of $2.13, remaining 38.2% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$16.90M↓ | -$15.62M↓ | -$14.13M↑ | -$15.50M↑ | -$16.32M |
| Net Income | -$15.35M↓ | -$15.16M↓ | -$13.50M↑ | -$14.70M↑ | -$15.39M |
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-2...